Proteomic techniques are promising strategies in the surveillance of hepatocellular carcinoma (HCC). This study aimed to investigate the serum profiling with magnetic bead (MB) and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) and to further identify the biomarkers for HCC. Serum samples from 80 chronic hepatitis B (CHB) patients, 94 HCC concomitant with HBV patients and 24 healthy subjects were examined by MALDI-TOF MS after peptide enrichment on MBs. Based on the genetic algorithm, diagnostic models for HCC were established between 30 HCC patients and 24 healthy subjects/30 CHB patients. Validations were done with the remaining cases. Markers in the models were identified through liquid chromatography (LC)/MS -MS. The three groups were well separated from each other and two discrimination models were established for HCC. The overall recognition capability of these two models was 96.25% and 93.33%, respectively. Validations showed the misdiagnosis ratio for HCC was 1.6% and 23.4%, respectively. The identified biomarkers for HCC included prothrombin precursor (fragment), calcium-dependent secretion activator 1, Baculoviral inhibitor of apoptosis repeat-containing protein 6, etc. MB-based MALDI-TOF MS is applicable in identifying the serum biomarkers and can be used in the surveillance of HCC among HBV-infected patients.
Introduction
Liver cancer is the third leading cause of cancer deaths worldwide [1] . Most liver cancer patients are in developing countries, and Chinese account for more than a half [2] . A majority of liver cancers are hepatocellular carcinomas (HCC), and the major risk factors for which are chronic infections with the hepatitis B virus (HBV) and C virus [3] . As HBV is more prevalent in China, more attention has been paid to the HBV infection in order to understand and further prevent disease progression. Among the 2 billion of people with HBV infection, 360 million are ended in chronic infection, as estimated by the World Health Organization [4] . The final outcomes of chronic HBV infection will be liver cirrhosis and HCC. Globally, 30% of cirrhosis and 50% of HCC can be attributed to HBV [5] . Owing to the high burden as a result of HBV chronic infection, it is imperative to find reliable, reproducible, and non-invasive biomarkers and/or a surveillance model for HCC in the HBV-infected population. The most widely used serum biomarker for HCC is alpha-fetoprotein (AFP). Up to 40% of HCC patients present with normal AFP level [6] and elevated AFP level can also be observed in patients with chronic hepatitis or cirrhosis [7, 8] . Therefore, the low sensitivity and specificity of AFP to HCC is a critical problem in the monitoring HCC. However, no other serum biomarkers have been identified to be as effective as AFP.
Proteomic techniques are promising tools for the discovery and subsequent identification of proteins and peptides associated with various diseases [9] . Mass spectrometry (MS)-based proteomics has been applied in clinical practice [10, 11] . The development of matrix-assisted laser desorption/ionization time-of-flight MS (MALDI-TOF MS) has provided a powerful tool for biomarkers discovery in different kinds of cancers such as ovarian cancer [12] , prostate cancer, bladder or breast cancer [13] , pancreas cancer [14] , oral cancer [15] , lung cancer, and neck and head cancer [16, 17] . Analysis of the proteomic profiling of HCC through MALDI-TOF MS has also been explored [18] . When compared with other laborious and time-consuming techniques in proteomic researches such as two-dimensional (2-D) gel electrophoresis, magnetic beads (MBs) based MALDI-TOF MS technology is a rapid, robust, and precise strategy for the investigation of complex blood samples [19, 20] . The high sensitivity and reproducibility of the MB-based platform for proteomic profiling has been highlighted [21] .
The aim of this study was to assess the proteomic profiles of serum of patients with or without HCC in the context of HBV infection using MALDI-TOF MS. This strategy enabled us to define optimal discriminatory protein profiles between HBV patients with and without HCC, and to identify effective serum biomarkers or to develop certain diagnostic models for HCC.
Materials and Methods
Sample collection Blood samples were collected in Zhongshan Hospital, Fudan University (Shanghai, China) from the following patients: (i) 80 Chinese patients with chronic hepatitis B (CHB) and receiving regular follow-up in the clinic for hepatitis from January 2008 to April 2008; (ii) 94 Chinese patients with pathologically proven HCC and HBV infection, who were hospitalized from January 2008 to April 2008 in the Liver Surgery Department of Zhongshan Hospital. Blood samples were collected before surgery. In addition, clinical information, including age, sex, cause of disease, and AFP level, were collected. Twenty-four healthy subjects served as controls. The healthy subjects were those who were HBsAg negative, and had no evidence for malignant tumor, no chronic disease, and no dysfunction of vital organs.
The hepatitis B was diagnosed according to the CHB Prevention and Treatment Guideline developed by the Society of Infectious Disease and Society of Liver Disease, Chinese Medical Association [22] . Our study was approved by the Ethics Committee of Zhongshan Hospital. Informed consent was obtained from each patient before study. Blood samples were collected in BD Vacutainer TM SST tubes (Franklin Lakes, USA), allowed to clot at 48C for 1 h, and centrifuged at 1600 g for 10 min at room temperature. Aliquots (100 ml) of serum was collected and stored at 2808C until use.
Sample processing
ClinProt magnetic beads WCX (weak cation exchange; Bruker Daltonik, Leipzig, Germany) were utilized. For each sample, 5 ml of serum was mixed with 10 ml of beads. The samples were purified on a ClinProt robotic platform (Bruker Daltonik) according to the manufacturer's instructions. Unbound proteins were discarded, and bound proteins were eluted. The eluate (0.8-1.2 ml) was added into 5 ml of 0.4 mg/ml alpha-cyano-4-hydroxycinnamic acid (HCCA) solution (HCCA in 1.2 mg/ml acetone solution mixed with ethanol at the volume ratio of 1:2). Samples were spotted robotically by depositing 0.8-1.2 ml of eluate onto an AnchorChip target (Bruker Daltonik; 600 mm anchors).
MALDI-TOF MS analysis
Mass spectra were acquired in a linear positive ion mode in the m/z range of 1000-20,000 using an Autoflex II MALDI-TOF/TOF mass spectrometer controlled by FlexControl software v. 2.0 (Bruker Daltonik). The instrument was equipped with a SmartBeam laser (Bruker Daltonik), and acquisition laser power was optimized using the polystyrene (PS) calibration mixture before the collection of data. Default operating conditions were as follows: ion source, 120.0 kV; ion source, 218.6 kV; lens voltage, 7.6 kV; pulsed ion extraction time, 320 ns; polarity, positive; matrix suppression mode, gating; gating strength, maximum; suppress up to, 600 Da; detector gain, 1400-1500 V; sample rate, 1.00 Gs/s; electronic gain, enhanced, 100 mV; real-time smooth, high; laser frequency, 20 Hz; laser attenuator, offset: 73%, range: 20%. All acquisitions were generated automatically in the instrument software and based on averaging 1000 shots from 10 nonoverlapping positions (100 shots/position). The profiling spectra were calibrated externally with a mixture of protein/ peptide calibrators (Bruker Daltonics). All spectra were processed by automatic baseline subtraction, peak detection, recalibration, and peak-area calculation according to the pre-defined settings. The criteria for peak detection were as follows: signal-to-noise ratio .5, a 2 Da peak width filter, and a maximum peak number of 200.
Data analysis
The spectra obtained from MALDI-TOF MS were analyzed using FlexAnalysis and ClinProt TM software (Bruker Daltonics). The former was to detect the peak intensity of interest and the latter to compile the peaks across the spectra obtained from all samples. ClinProt software version 2.0 was used to baseline subtract, normalize spectra (using total ion current), and determine peak m/z values and intensities in the mass range of 1000-10,000 m/z. To align the spectra, a mass window of 0.5% was used. For each comparison, the raw intensity was [14, 23] were applied for multivariate analysis aiming to establish the diagnostic models for HCC. GA is a method that can help finding an optimal solution to some problem by conducting random searches. Mahalanobis distance is a measure of the separation between two groups of samples. In our study, we ran the GA 100 times to identify sets of five peaks that have large Mahalanobis distance between serum profiles in HCC patients and those in other groups. Peaks that were significant according to the U test or that were included in a solution by GA were chosen for the final model-building step using an iterative, forward-selection, and greedy algorithm. We began with the peak P1 that had the largest statistic value. Given a set of peaks fP1, P2, . . ., Pkg, we then ordered all peak sets of the form fP1, P2, . . ., Pk, Qg, as Q varies, by the Mahalanobis distance between different samples. If the classification error on the training set was decreased by one of the top 10 peak sets, we added this peak to the working set and continued. We stopped when the training classification error was stabilized. As the GA uses randomness to locate approximate maxima, the result may be different each time; therefore, we ran 100 iterations from different starting points. The algorithm stops when the classification rate on the training set stops improving. Then, a 20% leave-one-out cross-validation was performed.
Validation of the models was done in the remaining 50 hepatitis B patients and 64 HCC patients. The discriminatory power for each putative marker in the diagnostic model was further described via analysis of area under the receiver operating characteristic (ROC) curve (AUC) using 
Results

General description
There were 52-157 peaks in the controls, 69 -172 peaks in the hepatitis B patients, and 92-184 peaks in the HCC patients. An average Tenancy in Common (TIC) overlay for every two of the three groups were shown with interest parts enlarged.
Univariate analysis
A total of 25 peaks were different (P , 0.05) between controls and hepatitis B patients ( Table 1) . Among these peaks, m/z 4053.82 and m/z 5395.73 showed the most significantly different peak area between these two groups [ Fig. 1(A) ]. Applying these two peaks as x-axis and y-axis, respectively, the distribution of 24 normal controls and 28 hepatitis B patients were displayed in Fig. 1(B) . A total of 42 peaks were different (P , 0.05) between controls and HCC patients ( Table 2) . Among these peaks, m/z 2899.47 and m/z 5264.53 showed the most significantly different peak area between these two groups [ Fig. 2(A) ]. Applying the two peaks as x-axis and y-axis, respectively, the distribution of 24 controls and 30 HCC patients were displayed in Fig. 2(B) . A total of 29 peaks were different (P , 0.05) between hepatitis B patients and HCC patients ( Table 3) . Among these peaks, m/z 4090.87 and m/z 4121.11 showed the most significantly different peak area between these two groups [ Fig. 3(A) ]. Applying these two peaks as x-axis and y-axis, respectively, the distribution of 30 hepatitis B patients and 30 HCC patients were displayed in Fig. 3(B) .
Multivariate analysis Discrimination models were established between the HCC group and other groups with GA. There were five peaks in the model for the discrimination of HCC patients from healthy patients, and the m/z was 2990.52, 5336.81, 4963.91, 1886.96, and 2951.85, respectively. The 20% leave-one-out cross validation was applied. During the analysis, the training model could identify 90.63% and 82.61% of HCC patients and healthy subjects, respectively. The overall recognition capability of the discrimination model was 96.25%. The ROCs and AUCs of the five peaks are shown in Fig. 4 . Another five peaks were enrolled in the model discriminating HCC patients and hepatitis B patients. The m/z was 4090.87, 5248.49, 4963.36, 2660.68, and 3954.9, respectively. The 20% leave-one-out cross-validation was applied. During the analysis, the training model could identify 67.74% and 82.76% of HCC patients and hepatitis B patients, respectively. The overall recognition capability of the discrimination model was 93.33%. The ROCs and AUCs of the five peaks are shown in Fig. 5 .
Validation of discrimination model and identification of potential markers
The remaining 64 HCC patients and 50 hepatitis B patients were recruited for the validation of the diagnostic models for HCC. In the first model which consisted of m/z 2990.52, m/z 5336.81, m/z 4963.91, m/z 1886.96, and m/z 2951.85 discriminating HCC patients from healthy controls, only one (1.6%) out of 64 HCC patients was misdiagnosed. In the second model which , and m/z 3954.9 discriminating HCC patients from hepatitis B patients, 49 (76.6%) of 64 HCC patients were correctly diagnosed. And 84% of the hepatitis B patients were identified correctly. Using the MASCOT program, the MS/MS data were searched through IPI database .The peptides in the discrimination models for HCC are listed in Table 4 . The characteristics of all individuals are listed in Table 5 .
Discussion
The surveillance of HBV-infected population who are at risk of progression to HCC has always been an essential task of clinical management. However, no effective serum biomarkers and/or diagnostic models for HCC have been found. Our results showed that protein profiling technology based on MB enrichment and analysis by MALDI-TOF MS could discriminate serum protein expression patterns between hepatitis B patients and hepatitis B associated HCC patients. The widely used biomarker for HCC is AFP, which may have the misdiagnosis rate of nearly 50% in HCC patients when the cut-off value is set at 20 ng/ml. The two diagnostic models for HCC were established herein and results showed that these models could discriminate HCC patients from healthy controls and hepatitis B patients. For further validation, the remaining HCC patients and hepatitis B patients were recruited, and results showed that the sensitivity of these two models was 98.4% and 76.6%, respectively, both of which were significantly higher than that of AFP in this study. When compared with the increased AFP level that showed about onefourth of the HCC high-risk groups in this study, the specificity of the second model was also a little higher. The first model was developed between HCC patients and healthy subjects and included five peptides. Therefore, we speculate that this model can be applied in HCC surveillance among a wide range of population and is not confined to the HBV-infected groups. Among Proteomic profiling of HCC with MALDI-TOF MS all the markers in this model, the AUC of CAPS isoform 1 is the largest. CAPS is a cytosolic and peripheral membrane protein and essential for the exocytosis of secretory vesicles in neural/endocrine tissues [24] . As a matter of fact, the liver is also a large endocrine gland, which is always been neglected. Hepatocytes, Kupffer's cells and endothelial cells can secret a lot of cytokines, some of which compose the microenvironment in the liver. The cytokine microenvironment plays a critical role in the development and progression of HCC [25] . However, no study in depth has detailed the pathways involving in the biological behaviors of these secretory cells in the local HCC microenvironment. The role of CAPS isoform 1 as a biomarker for HCC is needed to be fully evaluated. The second model was developed between HCC patients and hepatitis B patients and included another five peptides. It could be applied in HCC surveillance among the population with chronic HBV infection. The AUC of prothrombin precursor fragment (m/z 2990.52) is the largest among these markers in the diagnostic model. Its level was much higher in HCC patients than that in healthy patients (P ¼ 0.0000015). Prothrombin precursor is synthesized and transformed to prothrombin in the liver. Increased expression of prothrombin precursor has been observed in hepatoma tissues, and suggested as a result of decreased transformation, leading to the synthesis of desgamma-carboxyprothrombin (DCP) [26] . DCP is also a HCC biomarker but not effective enough so far, the serum level of which has been found elevated in HCC patients. It is probable that elevated prothrombin precursor lies in upstream of DCP. We speculate it can be applied as an independent biomarker for HCC. If possible, prothrombin precursor together with DCP can be detected simultaneously for elevating the detection rate of HCC. These two models shared one marker, Baculoviral inhibitor of apoptosis repeat-containing protein 6 (Birc 6), the AUC of which was a little lower than that of above two. Birc 6 is a kind of antiapoptosis protein [27] . The tumor suppressor p53 is a downstream effector of Birc6 [28] . In our study, Birc 6 level was elevated in HCC patients. There has been no previous report about the relationship between the persistent proliferation of hepatoma cells and Birc 6. It is interesting and worth exploring whether Birc6 plays the anti-apoptotic role and whether there is direct relationship between Birc6 and p53 in the HCC carcinogenesis and/or progression. The other markers in these two models did not provide higher AUC values when they were evaluated alone. The significance of these peptides as independent biomarkers for HCC is required to be further studied. However, models composed of two or more of them may be more powerful in the predicting HCC. The diagnostic models built herein were different from those in previous studies [29, 30] . Our results may help us get an extensive sight about the serum proteomic profiling of HCC at molecular level and achieve a further understanding of HCC.
In conclusion, this MB-based MALDI-TOF MS approach is feasible in identifying serum biomarkers that can be used in the surveillance of HCC among HBV-infected population. The role of biomarkers in the biological blueprint of HCC is worth being paid further attention to. We speculate that the diagnostic models containing potential biomarkers for HCC may broaden the field of HCC surveillance in the future. Note: AFP was determined with Elecsys 2010 (Roche) and 20 ng/ml was considered as the normal upper limit.
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